Search Results - "Day, Wesley W"

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial by Gadde, Kishore M, Dr, Allison, David B, Prof, Ryan, Donna H, MD, Peterson, Craig A, MS, Troupin, Barbara, MD, Schwiers, Michael L, MS, Day, Wesley W, PhD

“…Summary Background Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases, cancer, and other…”
Get full text

Avanafil for the Treatment of Erectile Dysfunction: A Multicenter, Randomized, Double-Blind Study in Men With Diabetes Mellitus by Goldstein, Irwin, MD, Jones, LeRoy A., MD, Belkoff, Laurence H., DO, Karlin, Gary S., MD, Bowden, Charles H., MD, Peterson, Craig A., MS, Trask, Brenda A., BS, Day, Wesley W., PhD

“…Abstract Objective To prospectively assess the safety and effectiveness of the investigational phosphodiesterase 5 inhibitor avanafil to treat erectile…”
Get full text

Selectivity of Avanafil, a PDE5 Inhibitor for the Treatment of Erectile Dysfunction: Implications for Clinical Safety and Improved Tolerability by Wang, Run, Burnett, Arthur L., Heller, Warren H., Omori, Kenji, Kotera, Jun, Kikkawa, Kohei, Yee, Shiyin, Day, Wesley W., DiDonato, Karen, Peterson, Craig A.

“…Phosphodiesterase type 5 (PDE5) inhibitors are indicated for the treatment of erectile dysfunction (ED); however, they can also inhibit other PDE isozymes,…”
Get full text

Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity by Jordan, Jens, Astrup, Arne, Engeli, Stefan, Narkiewicz, Krzysztof, Day, Wesley W, Finer, Nick

“…Weight loss can reduce the increased cardiovascular risk associated with obesity. Pharmacotherapy is a recognized weight loss treatment option; however,…”
Get full text

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study by Garvey, W Timothy, Ryan, Donna H, Look, Michelle, Gadde, Kishore M, Allison, David B, Peterson, Craig A, Schwiers, Michael, Day, Wesley W, Bowden, Charles H

“…Background: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has…”
Get full text

Controlled‐Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) by Allison, David B., Gadde, Kishore M., Garvey, William Timothy, Peterson, Craig A., Schwiers, Michael L., Najarian, Thomas, Tam, Peter Y., Troupin, Barbara, Day, Wesley W.

“…A 56‐week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled‐release combination of phentermine and topiramate (PHEN/TPM…”
Get full text

Changes in Cardiovascular Risk Associated With Phentermine and Topiramate Extended-Release in Participants With Comorbidities and a Body Mass Index ≥27 kg/m2 by Davidson, Michael H., MD, Tonstad, Serena, MD, Oparil, Suzanne, MD, Schwiers, Michael, MS, Day, Wesley W., PhD, Bowden, Charles H., MD

“…The aim of this analysis was to evaluate changes in cardiovascular risk factors in obese patients with dyslipidemia and/or hypertension receiving phentermine…”
Get full text

Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release by GARVEY, W. Timothy, RYAN, Donna H, HENRY, Robert, BOHANNON, Nancy J. V, TOPLAK, Hermann, SCHWIERS, Michael, TROUPIN, Barbara, DAY, Wesley W

“…OBJECTIVE To evaluate over 108 weeks the effect of phentermine and topiramate extended release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or…”
Get full text

A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy by Mulhall, John P, Burnett, Arthur L, Wang, Run, McVary, Kevin T, Moul, Judd W, Bowden, Charles H, DiDonato, Karen, Shih, Winnie, Day, Wesley W

“…We evaluated the safety and efficacy of 100 and 200 mg avanafil for the treatment of adult males with erectile dysfunction after bilateral nerve sparing…”
Get more information

A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Safety and Efficacy of Avanafil in Subjects with Erectile Dysfunction by Goldstein, Irwin, McCullough, Andrew R., Jones, LeRoy A., Hellstrom, Wayne J., Bowden, Charles H., DiDonato, Karen, Trask, Brenda, Day, Wesley W.

“…Phosphodiesterase type 5 (PDE5) inhibitors have become standard treatment for erectile dysfunction (ED). To prospectively evaluate the safety and efficacy of…”
Get full text

Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2) by Davidson, Michael H, Tonstad, Serena, Oparil, Suzanne, Schwiers, Michael, Day, Wesley W, Bowden, Charles H

“…The aim of this analysis was to evaluate changes in cardiovascular risk factors in obese patients with dyslipidemia and/or hypertension receiving phentermine…”
Get full text

Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study by Hellstrom, Wayne J.G, Kaminetsky, Jed, Belkoff, Laurence H, Goldstein, Irwin, Tursi, James P, Uy, Jonathan, Peterson, Craig A, Bowden, Charles H, Day, Wesley W

“…Purpose We examined the therapeutic effects of avanafil 15 minutes after dosing in men with mild to severe erectile dysfunction. Materials and Methods This…”
Get full text

Orally-Effective, Long-Acting Sorbitol Dehydrogenase Inhibitors:  Synthesis, Structure−Activity Relationships, and in Vivo Evaluations of Novel Heterocycle-Substituted Piperazino-Pyrimidines by Chu-Moyer, Margaret Y, Ballinger, William E, Beebe, David A, Berger, Richard, Coutcher, James B, Day, Wesley W, Li, Jiancheng, Mylari, Banavara L, Oates, Peter J, Weekly, R. Matthew

“…Optimization of a previously disclosed sorbitol dehydrogenase inhibitor (SDI, II) for potency and duration of action was achieved by replacing the…”
Get full text

Low-Dose Estradiol Spray to Treat Vasomotor Symptoms : A Randomized Controlled Trial by BUSTER, John E, KOLTUN, William D, PASCUAL, Maria Luz G, DAY, Wesley W, PETERSON, Craig

“…To investigate the safety and efficacy of a transdermal estradiol (E2) spray in women with postmenopausal vasomotor symptoms. A randomized, double-blind,…”
Get full text

Rapid determination of oral pharmacokinetics and plasma free fraction using cocktail approaches : Methods and application by ALLEN, M. C, SHAH, T. S, DAY, W. W

“…To apply cocktail approaches for protein binding (PB) and pharmacokinetics (PK) within a discovery program as a means of providing timely systemic exposure…”
Get full text

WEIGHT LOSS AND CARDIOVASCULAR RISK REDUCTION OVER 2 YEARS WITH CONTROLLED-RELEASE PHENTERMINE-TOPIRAMATE by Davidson, Michael, Bowden, Charles H, Day, Wesley W

Get full text

Steady-State Pharmacokinetics Following Application of a Novel Transdermal Estradiol Spray in Healthy Postmenopausal Women by Morton, Terri L., Gattermeir, David J., Petersen, Craig A., Day, Wesley W., Schumacher, Robert J.

“…This study was designed to evaluate the steady‐state pharmacokinetics (PK) of estradiol and its metabolites, estrone and estrone sulfate, following application…”
Get full text

The effects of skin-to-skin contact, application site washing, and sunscreen use on the pharmacokinetics of estradiol from a metered-dose transdermal spray by Schumacher, Robert J., Gattermeir, David J., Peterson, Craig A., Wisdom, Charlene, Day, Wesley W.

“…OBJECTIVE:This study evaluated the transfer of estradiol by skin-to-skin contact and the influence of washing and sunscreen use on the absorption of estradiol…”
Get full text

Discovery of zoniporide: A potent and selective sodium–hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility by Guzman-Perez, Angel, Wester, Ronald T., Allen, Mary C., Brown, Janice A., Buchholz, Allan R., Cook, Ewell R., Day, Wesley W., Hamanaka, Ernest S., Kennedy, Scott P., Knight, Delvin R., Kowalczyk, Paul J., Marala, Ravi B., Mularski, Christian J., Novomisle, William A., Ruggeri, Roger B., Tracey, W.Ross, Hill, Roger J.

“…Zoniporide (CP-597,396) is a potent and selective inhibitor of NHE-1, which exhibits high aqueous solubility and acceptable pharmacokinetics for intravenous…”
Get full text

SAR and species/stereo-selective metabolism of the sorbitol dehydrogenase inhibitor, CP-470,711 by Chu-Moyer, Margaret Y., Ballinger, William E., Beebe, David A., Coutcher, James B., Day, Wesley W., Li, Jiancheng, Oates, Peter J., Weekly, R.Matthew

“…SAR studies on the stereoisomers of CP-470,711 suggested that in vivo epimerization was taking place in rats. Further metabolism studies revealed that no…”
Get full text